(Q44454922)

English

An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer

scientific article published on 4 November 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Bradley J. Monk

6

object named as

Bradley J Monk

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

author name string

Heather J Dalton

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Xinhua Yu

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Lilian Hu

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Daniel S Kapp

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Ivor Benjamin

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

John K Chan

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

language of work or name

0 references

publication date

4 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

124

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

199-204

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Weekly paclitaxel in the adjuvant treatment of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Cancer's next frontier: addressing high and increasing costs

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Willingness to pay for a quality-adjusted life year: in search of a standard

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.09.028

7 January 2021

Identifiers

10.1016/J.YGYNO.2011.09.028

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44454922&oldid=2032768755"